{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["3(4)"],"submitter":["Mehta A"],"pubmed_abstract":["Hsp90a's vital role in tumour survival and progression, together with its highly inducible expression profile in gliomas and its absence in normal tissue and cell lines validates it as a therapeutic target for glioma. Hsp90a was downregulated using the post-transcriptional RNAi strategy (sihsp90a) and a post-translational inhibitor, the benzoquinone antibiotic 17-AAG. Glioblastoma U87-MG and normal human astrocyte SVGp12 were treated with sihsp90a, 17-AAG and concurrent sihsp90a/17-AAG (combined treatment). Both Hsp90a gene silencing and the protein inhibitor approaches resulted in a dramatic reduction in cell viability. Results showed that sihsp90a, 17-AAG and a combination of sihsp90a/17-AAG, reduced cell viability by 27%, 75% and 88% (p < 0.001), respectively, after 72 h. hsp90a mRNA co"],"journal":["Cancers"],"pagination":["4228-44"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3763420"],"repository":["biostudies-literature"],"pubmed_title":["A novel therapeutic strategy for the treatment of glioma, combining chemical and molecular targeting of hsp90a."],"pmcid":["PMC3763420"],"pubmed_authors":["Shervington L","Munje C","Shervington A","Mehta A"],"additional_accession":[]},"is_claimable":false,"name":"A novel therapeutic strategy for the treatment of glioma, combining chemical and molecular targeting of hsp90a.","description":"Hsp90a's vital role in tumour survival and progression, together with its highly inducible expression profile in gliomas and its absence in normal tissue and cell lines validates it as a therapeutic target for glioma. Hsp90a was downregulated using the post-transcriptional RNAi strategy (sihsp90a) and a post-translational inhibitor, the benzoquinone antibiotic 17-AAG. Glioblastoma U87-MG and normal human astrocyte SVGp12 were treated with sihsp90a, 17-AAG and concurrent sihsp90a/17-AAG (combined treatment). Both Hsp90a gene silencing and the protein inhibitor approaches resulted in a dramatic reduction in cell viability. Results showed that sihsp90a, 17-AAG and a combination of sihsp90a/17-AAG, reduced cell viability by 27%, 75% and 88% (p < 0.001), respectively, after 72 h. hsp90a mRNA co","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Dec","modification":"2025-04-26T04:11:18.413Z","creation":"2020-05-22T16:28:18Z"},"accession":"S-EPMC3763420","cross_references":{"pubmed":["24213135"],"doi":["10.3390/cancers3044228"]}}